CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 79 enrolled
Drug / intervention
Insulin Lispro +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03368807
NCT03368807N/ACompleted

An Objective Assessment of Mealtime Bolus Insulin Behavior and Associated Factors

Eli Lilly and Company·observational·Posted Dec 11, 2017·Updated Aug 2, 2019

In Brief

An observational study evaluating Continuous Glucose Monitoring and Insulin Lispro for Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2. Completed, enrolled 79 participants across 6 sites.

Detailed Summary

The main purpose of this study is to estimate missed bolus insulin doses in diabetics. This is a 12-week, single-arm, outpatient, exploratory study with two study periods in Type 1 or Type 2 diabetics, with an investigational reusable injection pen, insulin, and a Continuous Glucose Monitoring (CGM) device.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedDec 11, 2017
Enrollment StartDec 11, 2017
Primary CompletionJun 12, 2018
Study CompletionJul 23, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.6 years ago

Interventions

Continuous Glucose Monitoringdevice

Commercially available

Insulin Lisprodrug

As prescribed.